Business

Intranasal drug developer Optinose announced that it has issued $80 million in senior secured notes as part of a $150 million debt financing agreement with Pharmakon Advisors. The company plans to issue another $30 million in notes by mid-February 2020, "subject to the achievement of minimum Xhance revenues and certain other conditions." Optinose's Xhance fluticasone … [Read more...] about Optinose announces $150 million debt financing from Pharmakon Advisors

Satsuma Pharmaceuticals has announced an underwritten initial public offering of 5,500,000 shares of its common stock at $15.00 per share, with expected gross proceeds of $82.5 million. The underwriters of the offering also get a 30-day option to purchase additional shares of common stock (up to a total of 825,000 shares) at the same price. The company's common stock … [Read more...] about Satsuma looks to raise $82.5 million in IPO for continued development of intranasal DHE

Inhaled insulin developer Dance Biopharm announced that it has signed an agreement with DarioHealth to integrate its smart soft mist inhaler into DarioHealth's digital platform. The integration, which will allow patients using the SMI to get usage data in real time through a mobile app, is expected to be completed in time for upcoming clinical trials and would be … [Read more...] about Dance Biopharm announces deal with DarioHealth

Hikma Pharmaceuticals has agreed to acquire two nasal sprays as well as unit-dose nasal spray manufacturing assets from Insys Therapeutics, the company said. In June 2019, Insys declared bankruptcy and said that it would sell all of its assets. Hikma did not say how much it paid for the naloxone and epinephrine nasal sprays. Insys announced results from a dose … [Read more...] about Hikma acquires naloxone and epinephrine nasal sprays from Insys

Perrigo announced that it has settled a lawsuit filed by Endo Pharmaceuticals in May 2019 that alleged infringement of patents related to Nascobal cyanocobalamin nasal spray which expire in 2024. The terms of the settlement were not disclosed. Perrigo Executive VP and President, Rx Pharmaceuticals Sharon Kochan said, "This settlement is another example of our … [Read more...] about Perrigo and Endo settle suit over Nascobal nasal spray

Third Pole Therapeutics said that it has received two new patents from the US Patent and Trademark Office covering its inhaled nitric oxide (iNO) delivery systems through at least 2038. The patents (No. 10,286,176 and No. 10,328,228) are titled "Systems and Methods for Generating Nitric Oxide" and "Systems and Methods for Ambulatory Generation of Nitric … [Read more...] about Third Pole Therapeutics gets US patents for inhaled nitric oxide delivery systems

The United States Patent and Trademark Office has granted US patent No. 10376465 ("Monovalent Metal Cation Dry Powders for Inhalation") to Pulmatrix, the company said.  The claims cover formulations of Pulmazole inhaled dry powder itraconazole, which is based on Pulmatrix's iSPERSE particle engineering technology. Earlier this year, Pulmatrix announce that it had … [Read more...] about Pulmatrix gets another US patent for iSPERSE formulations

Alvogen has acquired marketing rights to the Alvesco cliclesonide metered dose inhaler in a number of Central and Eastern European (CEE) countries from Covis Pharma, the company said. Terms of the deal, which includes Bulgaria, Czech Republic, Hungary, Kazakhstan, Latvia, Poland, Romania, Russia and Slovakia, were not disclosed. In November 2018, Covis announced … [Read more...] about Alvogen to distribute Alvesco ciclesonide MDI in Central European countries